Printer Friendly

Ganeden Biotech Allowed Board Spectrum Patent for Consumer and Military Version of Topical Antifungal.

Business, Health/Medical & Defense Editors



Patent Protection of Penetration Agent is Key for DOD Antifungal

Collaboration and all Topical Pipeline Products

Ganeden Biotech Inc, a Cleveland, OH based Biotechnology company, has received a formal Notice of Allowance from the United States Patent and Trademark Office protecting its topical antifungal product. When issued, the patent will protect the Company's entire line of dermal products including soon to be released formulations for acne, dandruff, eczema, and ringworms. The patent will also protect the use of the Company's dermal penetration agent in combination with all antifungal, antibacterial, and antiviral medications developed by other pharmaceutical and consumer product companies to combat dermal diseases.

According to Sean Farmer, Ganeden`s Founder & Chief Scientist; "this patent will enable the Company to greatly expand and improve our penetration agent for OTC and pharmaceutical dermal products." Also, "the patent establishes Ganeden's importance to the global market place for improving the efficacy of topical antifungals and has vital relevance to the military for deployment and field use of the antifungal lotions."

The consumer antifungal product, Clearly Confident(TM), will be available throughout the United States in the first quarter of 2003. The military version, Fungi-Free(TM) is currently being tested for the prevention and cure of toenail infections, athletes' feet and jock itch under a prestigious award issued by the Department of Defense's Congressionally Mandated Peer Reviewed Medical Research Program, administrated by U.S. Army Medical Research Acquisition Activity (USAMRAA) located at Fort Detrick, MD. The Company's DOD award is a collaborative effort with University Hospitals of Cleveland and Case Western Reserve University School of Medicine and the United States Marine Corps Systems Command located at Quantico, VA.

Ganeden Biotech is engaged in the discovery, development, and commercialization of therapeutic products based on the unique properties of lactic acid bacteria. The Company has identified a delivery system for lactic acid that has allowed them to overcome the manufacturing, stability, and delivery challenges that previously inhibited a therapeutic and commercial application of lactic acid bacteria.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 8, 2002
Previous Article:NuCORE Technology Receives the Investors' Choice Award.
Next Article:Pocketop Wireless PDA Keyboard Now Available at Over 300 Dixons Stores Across the UK; Following North American Success, Leading European Retailer to...

Related Articles
Antimicrobial patch dressing. (Product Spotlight).
Mealey to launch Litigation Report on Thimerosal & Vaccines.
Zero-sulfur future. (The Beat).
Topical antibiotics: strategies for avoiding ototoxicity.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters